Could a 7-Day antibiotic course every 8 weeks tame bronchiectasis Flare-Ups?
NCT ID NCT07274020
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether taking the antibiotic moxifloxacin for 7 days every 8 weeks (for a year) can reduce lung infection flare-ups in people with non-cystic fibrosis bronchiectasis. 140 adults who have had at least two flare-ups in the past year will be randomly assigned to either the intermittent moxifloxacin regimen plus standard care, or standard care alone. The main goal is to see if the antibiotic schedule lowers the number of exacerbations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Moxifloxacin (an antibiotic taken by mouth)
- What this could lead to
- If it works, this could give doctors a new way to reduce lung infections and hospital visits for people with bronchiectasis.
- What could go wrong
- This is a single-center trial with 140 people, so results may not apply to everyone. Moxifloxacin can cause serious side effects like tendon damage and nerve problems, and long-term antibiotic use may lead to drug resistance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIECTASIS, NON-CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Assiut University hospital
Asyut, Asyut Governorate, 71515, Egypt